Is BDX a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on A simpler, pure-play medtech after the Waters separation, with revenue (ttm, continuing operations) at ~$20.8 billion. The bear case rests on the most persistent risk is product liability: BD carries large ongoing litigation over hernia and pelvic mesh and IVC filters, and adverse verdicts or settlement waves can hit cash flow and headlines unpredictably. Analysts covering it are spread from $170.00 to $225.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The most persistent risk is product liability: BD carries large ongoing litigation over hernia and pelvic mesh and IVC filters, and adverse verdicts or settlement waves can hit cash flow and headlines unpredictably. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $170.00, -3.9% from the $176.86 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

A simpler, pure-play medtech after the Waters separation. The whole point of the February 2026 separation was to leave behind a focused medical technology company rather than a conglomerate spanning devices, life-science research tools and diagnostics. The most optimistic analyst target on BDX is $225.00, +27.2% from the $176.86 price. That figure is only reachable if this thesis works close to its best case.

The most persistent risk is product liability: BD carries large ongoing litigation over hernia and pelvic mesh and IVC filters, and adverse verdicts or settlement waves can hit cash flow and headlines unpredictably. Quality and regulatory risk is real and recurring for a device maker at this scale, including a 2026 voluntary recall of certain intraosseous vascular access needle sets and the multi-year FDA remediation history of the Alaris infusion pump. Customer power is a structural pressure, because hospitals buy through group purchasing organizations and integrated delivery networks that negotiate hard on commodity consumables such as syringes and catheters, while China volume-based procurement compresses pricing in that market. Tariffs, freight and input costs affect a business that ships enormous physical volumes across borders, and currency swings move reported results given large international exposure. Finally, the separation itself introduces execution risk: stranded costs, dis-synergies and a smaller revenue base against the debt taken on before the split all have to be managed, and the comparison history is now discontinuous, which makes trend analysis harder. The most pessimistic published target is $170.00, -3.9% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Becton, Dickinson and Company (BD) is a US medical technology maker of syringes, IV catheters, infusion systems, prefillable drug-delivery devices and interventional products.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (A simpler, pure-play medtech after the Waters separation) stalling in the reported numbers rather than in the narrative, the risk above (the most persistent risk is product liability: BD carries large ongoing litigation over hernia and pelvic mesh and IVC filters, and adverse verdicts or settlement waves can hit cash flow and headlines unpredictably) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

BDX is the New York Stock Exchange ticker for Becton, Dickinson and Company, usually called BD. It is a medical technology company founded in 1897 and based in Franklin Lakes, New Jersey, that makes syringes, needles, IV catheters, infusion systems, prefillable drug-delivery devices and interventional products. After the February 2026 separation it operates in four segments: Medical Essentials, Connected Care, BioPharma Systems and Interventional.

Yes. BD completed the separation of its Biosciences and Diagnostic Solutions businesses and their combination with Waters Corporation on February 9, 2026, structured as a Reverse Morris Trust. BD shareholders received about 0.135 shares of Waters for each BD share held as of February 5, 2026 and ended up owning roughly 39.2% of the combined company, while BD received about $4 billion in cash. The divested business was valued at roughly $18.8 billion.

That depends on your goals, time horizon and risk tolerance, and nothing here is investment advice. The constructive case is a simpler post-separation medtech with heavily recurring consumables revenue, mid-single-digit organic growth, roughly 14 times forward earnings and a long dividend record. The cautious case is slow growth against faster-growing device peers, persistent mesh and IVC-filter product liability, hospital pricing pressure and the execution risk of standing up a smaller company. Weigh both against the rest of your portfolio.